Bisoprolol in Angina Pectoris

[1]  B Whiting,et al.  Population Pharmacokinetic Analysis of Bisoprolol , 1989, Clinical pharmacokinetics.

[2]  F. Burkart,et al.  [A new beta 1-receptor blocker in the therapy of essential hypertension and angina pectoris]. , 1989, Schweizerische medizinische Wochenschrift.

[3]  W. Prager,et al.  Effect of β-adrenergic Blockade on the Circadian Rhythm of Myocardial Ischemia in Ambulatory Patients with Stable Angina , 1989 .

[4]  E M Sorkin,et al.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. , 1988, Drugs.

[5]  M. Salvatore,et al.  Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil. , 1987, European heart journal.

[6]  C. Ioannides,et al.  Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease. , 1987, European heart journal.

[7]  C. Ioannides,et al.  The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance. , 1987, European heart journal.

[8]  K. Lie,et al.  Comparison of the effects of two doses of bisoprolol on exercise tolerance in exercise-induced stable angina pectoris. , 1987, European heart journal.

[9]  A. Wellstein,et al.  Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. , 1987, European heart journal.

[10]  A. Camm,et al.  A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris. , 1987, European heart journal.

[11]  B. Maisch,et al.  T suppressor cell activity in (peri)myocarditis and infective endocarditis , 1987 .

[12]  W. Kirch,et al.  Pharmacokinetics of Bisoprolol During Repeated Oral Administration to Healthy Volunteers and Patients with Kidney or Liver Disease , 1987, Clinical pharmacokinetics.

[13]  K. Bühring,et al.  Basic Pharmacokinetics of Bisoprolol, a New Highly Beta1‐selective Adrenoceptor Antagonist , 1986, Journal of clinical pharmacology.

[14]  M. Pfisterer,et al.  Acute Hemodynamic Effects of Bisoprolol, a New β1, Selective Adrenoreceptor Blocking Agent, in Patients with Coronary Artery Disease , 1986 .

[15]  H. Wiemann,et al.  Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist. , 1986, British journal of clinical pharmacology.

[16]  G. Leopold.  Balanced Pharmacokinetics and Metabolism of Bisoprolol , 1985, Journal of cardiovascular pharmacology.

[17]  H. Roskamm,et al.  Effect of Bisoprolol on Exercise Tolerance in Patients with Coronary Heart Disease: Placebo‐Controlled Double‐Blind Crossover Study , 1985, Journal of cardiovascular pharmacology.

[18]  P. Esente,et al.  Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease. , 1986, Journal of cardiovascular pharmacology.

[19]  R. Zochowski,et al.  Intravenous clonidine treatment in acute myocardial infarction (with comparison to a nitroglycerin-treated and control group). , 1986, Journal of cardiovascular pharmacology.

[20]  G. Schultz,et al.  Vascular smooth muscle: availability of calcium through alpha-adrenoceptor stimulation. , 1986, Journal of cardiovascular pharmacology.

[21]  A. Simon,et al.  Evidence of early changes of the brachial artery circulation in borderline hypertension. , 1986, Journal of cardiovascular pharmacology.

[22]  G. Wagner,et al.  [Effect of bisoprolol in coronary heart disease. Effect on cardiovascular parameters and ischemic ST depression: studies on the duration of the effect]. , 2008, Deutsche medizinische Wochenschrift.